Indian pharma leaders seek faster trials, state-backed market for new drugs
· Business Today Mkts
Kiran Mazumdar-Shaw flags regulatory delays; Glenmark's Glenn Saldanha calls for reimbursement support for life-saving…
The analysis
Because the driver here is macro rather than company-specific, the read-through is to index-level positioning rather than to any single name — correlations tend to rise when the whole market faces the same signal.
Market context
- This is a market-wide development — its reach goes beyond any single stock.
- Sector exposure: Pharma & Healthcare.
In this story
Related coverage
8 midcap stocks rally up to 135% in a year; 2 turn multibaggers
Anthem Biosciences block deal: Portsmouth Technologies sells 30 lakh shares worth Rs 250 crore
JioBlackRock Flexicap down 6.67% in 2026: 19 fresh buys, 18 exits in September reshuffle
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month